分子肿瘤表观在临床决策中的应用仍是一个挑战。为了帮助解释复杂的生物标志物，全球范围内建立了分子肿瘤委员会（MTBs）。在本研究中，我们表明多学科方法对MTBs的成功至关重要。我们的MTB由儿科肿瘤学家、病理学家和药剂师组成，评估了2016年3月至2021年9月间诊断的115例病例。如果发现可靶向的突变，药剂师会根据药物可获得性评估治疗选择。分子检测发现可治疗的遗传改变最常涉及细胞周期。在评估的85%的病例中，我们的MTB根据患者的历史和分子肿瘤测试结果提供了治疗建议。然而，只有三名患者接受了MTB推荐的靶向治疗，其中只有一名患者展示出改善的临床结局。对于其余患者，MTB推荐的治疗通常由于分子肿瘤分析在疾病过程的晚期才进行而未被实施。对于接受MTB推荐治疗的三名患者来说，由于医生偏好，治疗在诊断后数月才实施。因此，教育医疗保健提供者关于靶向治疗的好处，可能增加这些新型药物的接受度，从而提高患者的生存率。

The application of molecular tumor profiles in clinical decision making remains a challenge. To aid in the interpretation of complex biomarkers, molecular tumor boards (MTBs) have been established worldwide. In the present study, we show that a multidisciplinary approach is essential to the success of MTBs. Our MTB, consisting of pediatric oncologists, pathologists, and pharmacists, evaluated 115 cases diagnosed between March 2016 and September 2021. If targetable mutations were identified, pharmacists aided in the evaluation of treatment options based on drug accessibility. Treatable genetic alterations detected through molecular testing most frequently involved the cell cycle. For 85% of the cases evaluated, our MTB provided treatment recommendations based on the patient's history and results of molecular tumor testing. Only three patients, however, received MTB-recommended targeted therapy, and only one of these patients demonstrated an improved clinical outcome. For the remaining patients, MTB-recommended treatment often was not administered because molecular tumor profiling was not performed until late in the disease course. For the three patients who did receive MTB-recommended therapy, such treatment was not administered until months after diagnosis due to physician preference. Thus, the education of healthcare providers regarding the benefits of targeted therapy may increase acceptance of these novel agents and subsequently improve patient survival.